Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Losartan
Drug ID BADD_D01322
Description Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored.[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]
Indications and Usage May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Marketing Status Prescription; Discontinued
ATC Code C09CA01
DrugBank ID DB00678
KEGG ID D08146
MeSH ID D019808
PubChem ID 3961
TTD Drug ID D0DD0K
NDC Product Code Not Available
Synonyms Losartan | 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol | DuP-753 | DuP 753 | DuP753 | MK-954 | MK 954 | MK954 | Cozaar | Losartan Potassium | Potassium, Losartan | Losartan Monopotassium Salt | Monopotassium Salt, Losartan | Salt, Losartan Monopotassium
Chemical Information
Molecular Formula C22H23ClN6O
CAS Registry Number 114798-26-4
SMILES CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Capillary fragility increasedC-C motif chemokine 2P14844Not Available26156105
Capillary fragility increasedInterleukin-1 alphaP01583T1634026156105
Capillary fragility increasedInterleukin-10P29456Not Available26156105
Metabolic disorderCytochrome P450 2C9P11712T192449663807; 11434505; 9825828
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Refractory cytopenia with unilineage dysplasia16.01.04.007; 01.10.04.0070.000019%Not Available
Hepatic cancer16.07.02.004; 09.04.02.0080.000019%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.021--Not Available
Intestinal angioedema10.01.05.019; 07.08.03.012; 23.04.01.0190.000073%Not Available
Myeloproliferative neoplasm16.21.03.006; 01.13.03.0060.000013%Not Available
Abnormal loss of weight14.03.02.0190.000146%Not Available
Coeliac disease14.02.01.007; 10.04.04.012; 07.17.01.0080.000146%Not Available
Full blood count abnormal13.01.07.0030.000049%Not Available
Full blood count decreased13.01.07.004--Not Available
Mean cell haemoglobin increased13.01.05.0060.000049%Not Available
Metastases to bone15.09.03.006; 16.22.02.0050.000073%Not Available
Nucleated red cells01.07.02.0120.000049%Not Available
Renin increased13.09.02.0040.000049%Not Available
Serum ferritin abnormal13.11.01.0280.000170%Not Available
Thalassaemia03.15.03.002; 01.04.03.0010.000049%Not Available
Thalassaemia beta03.15.03.003; 01.04.03.0020.000049%Not Available
Terminal state08.01.03.0790.000097%Not Available
Anti-erythropoietin antibody positive13.01.03.0070.000194%Not Available
Intestinal villi atrophy07.11.03.0100.000049%Not Available
Transferrin saturation decreased13.11.01.0510.000121%Not Available
Allergic cough22.02.03.011; 10.01.03.0400.000049%Not Available
Delayed fontanelle closure15.10.05.0030.000019%Not Available
Clostridium difficile infection11.02.02.009--Not Available
Cardiac stress test abnormal13.14.02.0160.000049%Not Available
Nephrogenic anaemia20.01.01.007; 01.03.04.0010.000073%Not Available
General physical condition abnormal13.15.01.0400.000049%Not Available
Cerebrosclerosis17.11.01.0150.000073%Not Available
Investigation abnormal13.18.01.0020.000049%Not Available
Anti-erythropoietin antibody13.01.03.0050.000049%Not Available
Extramedullary haemopoiesis01.05.01.0210.000049%Not Available
The 18th Page    First    Pre   18 19    Next   Last    Total 19 Pages